These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27546214)

  • 1. Human Serum Albumin and HER2-Binding Affibody Fusion Proteins for Targeted Delivery of Fatty Acid-Modified Molecules and Therapy.
    Dong D; Xia G; Li Z; Li Z
    Mol Pharm; 2016 Oct; 13(10):3370-3380. PubMed ID: 27546214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
    J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting.
    Hoppmann S; Miao Z; Liu S; Liu H; Ren G; Bao A; Cheng Z
    Bioconjug Chem; 2011 Mar; 22(3):413-21. PubMed ID: 21299201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human serum albumin and p53-activating peptide fusion protein is able to promote apoptosis and deliver fatty acid-modified molecules.
    Joshi MR; Yao N; Myers KA; Li Z
    PLoS One; 2013; 8(11):e80926. PubMed ID: 24278348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.
    Altai M; Liu H; Ding H; Mitran B; Edqvist PH; Tolmachev V; Orlova A; Gräslund T
    J Control Release; 2018 Oct; 288():84-95. PubMed ID: 30172673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fusion of an albumin-binding domain extends the half-life of immunotoxins.
    Guo R; Guo W; Cao L; Liu H; Liu J; Xu H; Huang W; Wang F; Hong Z
    Int J Pharm; 2016 Sep; 511(1):538-549. PubMed ID: 27457423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate.
    Ghanemi M; Pourshohod A; Ghaffari MA; Kheirollah A; Amin M; Zeinali M; Jamalan M
    Curr Cancer Drug Targets; 2019; 19(1):65-73. PubMed ID: 28460618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging.
    Honarvar H; Jokilaakso N; Andersson K; Malmberg J; Rosik D; Orlova A; Karlström AE; Tolmachev V; Järver P
    Nucl Med Biol; 2013 Apr; 40(3):378-86. PubMed ID: 23357083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Affibody-conjugated 5-fluorouracil prodrug system preferentially targets and inhibits HER2-expressing cancer cells.
    Lan KH; Tsai CL; Chen YY; Lee TL; Pai CW; Chao Y; Lan KL
    Biochem Biophys Res Commun; 2021 Dec; 582():137-143. PubMed ID: 34710829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific targeting of HER2-positive human breast carcinoma SK-BR-3 cells by amygdaline-Z
    Moradipoodeh B; Jamalan M; Zeinali M; Fereidoonnezhad M; Mohammadzadeh G
    Mol Biol Rep; 2020 Sep; 47(9):7139-7151. PubMed ID: 32929653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for high-affinity HER2 receptor binding by an engineered protein.
    Eigenbrot C; Ultsch M; Dubnovitsky A; Abrahmsén L; Härd T
    Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15039-44. PubMed ID: 20696930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule.
    Friedman M; Lindström S; Ekerljung L; Andersson-Svahn H; Carlsson J; Brismar H; Gedda L; Frejd FY; Ståhl S
    Biotechnol Appl Biochem; 2009 Aug; 54(2):121-31. PubMed ID: 19492986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule.
    Nishimura Y; Mimura W; Mohamed Suffian IF; Amino T; Ishii J; Ogino C; Kondo A
    J Biochem; 2013 Mar; 153(3):251-6. PubMed ID: 23235317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
    Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
    J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Serum Albumin Domain I Fusion Protein for Antibody Conjugation.
    Patterson JT; Wilson HD; Asano S; Nilchan N; Fuller RP; Roush WR; Rader C; Barbas CF
    Bioconjug Chem; 2016 Oct; 27(10):2271-2275. PubMed ID: 27666414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
    Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
    J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aptamer functionalized curcumin-loaded human serum albumin (HSA) nanoparticles for targeted delivery to HER-2 positive breast cancer cells.
    Saleh T; Soudi T; Shojaosadati SA
    Int J Biol Macromol; 2019 Jun; 130():109-116. PubMed ID: 30802519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human serum albumin dimer has high blood circulation activity and low vascular permeability in comparison with native human serum albumin.
    Matsushita S; Chuang VT; Kanazawa M; Tanase S; Kawai K; Maruyama T; Suenaga A; Otagiri M
    Pharm Res; 2006 May; 23(5):882-91. PubMed ID: 16715378
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.